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Abstract
Objectives: This study aimed to evaluate the seventh edition of the American Joint Committee on
Cancer (AJCC) tumour–node–metastasis (TNM) staging system and to compare its efficacy with those of
the fifth and sixth editions of the AJCC staging system and the TNM staging system defined by the Liver
Cancer Study Group of Japan.
Methods: Data for 754 patients submitted to hepatectomy for hepatocellular carcinoma (HCC) between
1989 and 2005 were reviewed. Tumour-free survival was estimated using the Kaplan–Meier method and
compared between subgroups using the log-rank test. Prognostic factors for tumour-free survival were
identified by multivariable analysis. The accuracy of these staging systems was evaluated using the Cox
regression model and a refined staging system was developed based on the drawbacks of the respective
systems.
Results: According to the criteria defined by the seventh AJCC TNM staging system, 5-year survival was
50.6% in patients with T1 tumours, 21.0% in patients with T2 tumours, 14.6% in patients with T3a
tumours, 12.1% in patients with T3b tumours, and 12.9% in patients with T4 tumours. There was no
survival difference between patients with T3a and T3b tumours (P = 0.073), nor between those with T3b
and T4 tumours (P = 0.227). Significant prognostic tumour factors were microvascular invasion, tumour
multiplicity, bilobar disease and a tumour size of 5.0 cm. The fifth and sixth editions of the AJCC TNM
staging system were found to be more accurate in prognosis than the seventh.
Conclusions: The seventh edition of the AJCC TNM staging system is able to adequately stratify
patients with early HCC only. A refined staging system is therefore proposed.
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Introduction
Hepatocellular carcinoma (HCC) is the fifth most common
malignancy in the world.1 Each year, 500 000–1 000 000 new
cases are reported and around 600 000 patients die of this cancer
globally.2,3 Hepatic resection and liver transplantation remain the
curative treatments that attain longterm survival. Nonetheless,
stringent patient selection criteria and the shortage of liver grafts
have restricted the widespread application of liver transplanta-
tion to patients with early HCC. By contrast, longterm prognosis
after hepatic resection is often influenced by postoperative
tumour recurrence.4,5 Tumour characteristics that determine the
biological aggressiveness and metastatic potential of the disease
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are therefore important prognostic markers for longterm
survival6–8 and hence important elements in the staging of HCC.
In 2003, a consensus panel jointly organized by the American
Hepato-Pancreato-Biliary Association (AHPBA) and the Ameri-
can Joint Committee on Cancer (AJCC) concluded that the two
different categories (i.e. clinical and pathological) of staging
systems for HCC should embrace the entire spectrum of the dis-
ease.9 A pathological staging system for HCC is one that is desig-
nated solely for HCC patients undergoing hepatic resection or
liver transplantation. To date, there are two widely accepted
pathological staging systems for HCC, one developed by the AJCC
and the other by the Liver Cancer Study Group of Japan
(LCSGJ).10,11 Both of them use T (tumour: tumour size, number
and nearby invasion), N (node: regional lymph node involve-
ment) and M (metastasis: distant metastasis) as parameters to
stage the disease.
The AJCC has in fact developed several editions of its TNM
staging system. A major drawback of the fifth AJCC TNM staging
system (Table 1), which is an earlier edition, is that its clinical
application is complex and thus it fails to stratify patients accord-
ingly. To address this issue, a simplified sixth edition (Table 2) was
released in 2002.12 Both systems use tumour size and number,
vascular invasion, perforation of the visceral peritoneum, and
invasion into adjacent organs as parameters for T-staging. Recent
data have shown that the sixth edition of the TNM staging system
also fails to demonstrate accuracy in predicting longterm survival
in patients undergoing hepatic resection.13 The seventh AJCC
TNM staging system (Table 3), which is the latest edition, was
released in 2009. It subclassifies advanced-stage tumours with
reference to tumour multifocality and portal vein invasion.14
However, its prognostic accuracy has yet to be validated in pro-
spective clinical studies. By contrast, the LCSGJ TNM staging
system (Table 4) has been validated in Japanese15 and in Chinese16
patients and compared with the fifth and sixth editions of the
AJCC staging system.16
In the present study, the survival outcomes of 754 HCC patients
who received curative hepatic resection at a single centre were
reviewed. The fifth, sixth and seventh AJCC and the LCSGJ TNM
staging systems were evaluated on their respective abilities to
predict disease-free survival (DFS). Independent prognostic
factors for longterm survival were identified by multivariable
analysis and then integrated into a refined staging system. The
prognostic ability of the refined staging system was compared
with the capabilities of the other staging systems.
Table 1 American Joint Committee on Cancer tumour–node–
metastasis (TNM) system for staging of primary liver cancer, fifth
edition
Stage Tumour Node Metastasis
I T1 N0 M0
II T2 N0 M0
IIIa T3 N0 M0
IIIb T1, T2, or T3 N1 M0
IVa T4 Any N M0
IVb Any T Any N M1
T1, solitary tumour of 2.0 cm without vascular invasion.
T2, solitary tumour of 2.0 cm with vascular invasion, or multiple unilo-
bar tumours of 2.0 cm without vascular invasion, or solitary tumours of
>2.0 cm without vascular invasion.
T3, solitary tumour of >2.0 cm with vascular invasion, or multiple unilobar
tumours of 2.0 cm with vascular invasion, or multiple unilobar tumours
of >2.0 cm with or without vascular invasion.
T4, multiple bilobar tumours, or with invasion of a major branch of the
portal or hepatic vein, or with invasion of an adjacent organ other than
the gallbladder, or with perforation of the visceral peritoneum.
N1, regional lymph node metastasis.
M1, distant metastasis.
Table 2 American Joint Committee on Cancer tumour–node–
metastasis (TNM) system for staging of primary liver cancer, sixth
edition
Stage Tumour Node Metastasis
I T1 N0 M0
II T2 N0 M0
IIIa T3 N0 M0
IIIb T4 N0 M0
IIIc Any T N1 M0
IV Any T Any N M1
T1, single tumour without vascular invasion.
T2, single tumour with vascular invasion, or multiple tumours none of are
>5.0 cm.
T3, multiple tumours any of which are >5.0 cm, or involving a major
branch of the portal or hepatic vein.
T4, with direct invasion of an adjacent organ other than the gallbladder or
with perforation of the visceral peritoneum.
N1, regional lymph node metastasis.
M1, distant metastasis.
Table 3 American Joint Committee on Cancer tumour–node–
metastasis (TNM) system for staging of primary liver cancer, seventh
edition
Stage Tumour Node Metastasis
I T1 N0 M0
II T2 N0 M0
IIIa T3a N0 M0
IIIb T3b N0 M0
IIIc T4 N0 M0
IVa Any T N1 M0
IVb Any T Any N M1
T1, single tumour without vascular invasion.
T2, single tumour with vascular invasion, or multiple tumours, none of
>5.0 cm.
T3a, multiple tumours, any of which are >5.0 cm.
T3b, involving a major branch of the portal or hepatic vein.
T4, with direct invasion of an adjacent organ other than the gallbladder,
or with perforation of the visceral peritoneum.
N1, regional lymph node metastasis.
M1, distant metastasis.
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Materials and methods
This was a retrospective study that required no institutional
approval. From January 1989 to December 2005, 841 patients
underwent curative hepatic resection for HCC at the Queen
Mary Hospital, Hong Kong. The operative technique for hepatic
resection has been reported previously.17 Patients who demon-
strated positive resection margins (n = 47) and patients who
died postoperatively (n = 40) were excluded from the study.
Clinicopathological data for the remaining 754 patients were
reviewed. All of these patients had been followed up for 60
months at the time of data analysis. Data were censored in
December 2011.
For the purpose of this study, major vascular invasion was
defined as tumour invasion into the first branch of the portal or
first tributary of the hepatic vein. Microvascular invasion (MVI)
was defined as the presence of tumour emboli within the tribu-
taries of the hepatic vein or branches of the portal vein. In patients
with multiple tumours, MVI referred only to the predominant
tumour nodule. Tumour invasion into adjacent organs (except the
gallbladder) was confirmed by gross examination of the resected
specimens and/or histological examination. Tumour perforation
into the peritoneum (i.e. ruptured HCC) was defined as the pres-
ence of peritumoral haematoma within the peritoneal cavity. As
lymph node metastasis is uncommon in resectable HCC,18–20
routine lymphadenectomy was not performed at the study centre.
Data with which to assess the prognostic impact of lymph node
metastasis were insufficient and thus N status was not evaluated in
the present study.
Follow-up protocol for surveillance of HCC
The follow-up protocol for tumour surveillance included com-
puted tomography (CT) at 1 month after resection to confirm
gross tumour clearance and subsequently at every 3 months. In
patients with chronic renal impairment or known allergy to i.v.
contrast material, magnetic resonance imaging (MRI) was per-
formed instead. The latter was also performed when CT findings
were ambiguous in terms of tumour recurrence. Serum liver bio-
chemistry was checked monthly in the first year after resection,
and every 3 months thereafter. Tumour recurrence was defined as
a new lesion with arterial enhancement and portal venous
washout on contrast-enhanced CT or MRI. Biopsy was generally
avoided for fear of needle tract seeding of tumour cells. All
follow-up data were prospectively recorded and survival data
were updated after each follow-up visit. No patient was lost to
follow-up.
Statistical analysis
Statistical analysis was performed using spss Version 16.0 (SPSS,
Inc., Chicago, IL, USA). Continuous variables were expressed as
medians (with interquartile ranges) and compared between
groups using the Mann–Whitney U-test. Categorical variables
were compared using the chi-squared test or Fisher’s exact test as
appropriate. Overall survival and DFS were estimated by the
Kaplan–Meier method and compared between the various sub-
groups using the log-rank test. The primary endpoint of the study
was DFS defined as the period from the time of hepatic resection
to the time of tumour recurrence or death related to HCC or
complications of liver failure. Overall survival was defined as the
period from the time of hepatic resection to the time of death
from any cause. Multivariable analysis using the proportional
hazard model was used to identify independent prognostic factors
affecting DFS. A P-value of <0.05 was considered to indicate sta-
tistical significance. Thereafter, each staging system was entered in
turn into Cox regression analysis to evaluate its correlation with
DFS. The degree of correlation was expressed in value as -2 log-
likelihood. A smaller value indicates a closer correlation between
the staging system and the full model. To reaffirm the association
of staging system with survival, each staging system was further
evaluated and ranked using Kendall’s tau rank correlation.
Results
Clinicopathological features of the 754 patients are shown in
Table 5. The cohort had a male preponderance. The median age of
the patients was 54 years. Most patients were hepatitis B virus
(HBV) carriers, but HCC had been detected on screening in just
over a third of patients. The majority of patients had Child–Pugh
class A cirrhosis.Major hepatic resections were performed as right
hepatectomy (40.0%), left hepatectomy (9.5%) or more extensive
resection (13.0%). Median perioperative blood loss was 600 ml;
75.4% of patients did not require blood transfusion.At the time of
data analysis, 299 patients remained alive on follow-up. The three
most common causes of death were terminal malignancy (83.0%),
variceal bleeding (5.0%) and liver failure (4.0%).
Table 6 shows the prognostic impact of 21 clinicopathological
factors associated with longterm DFS. Patient factors associated
with poor prognosis were male gender, serum bilirubin of
>12 mmol/l, serum aspartate transaminase (AST) of >48 U/l and
serum albumin of 41 g/dl. Tumour factors associated with poor
prognosis were symptomatic HCC, serum alpha-fetoprotein
(AFP) of >400 ng/ml, tumour diameter of >5.0 cm,moderately or
poorly differentiated tumour, bilobar tumours, multiple tumour
Table 4 Liver Cancer Study Group of Japan staging system for
primary liver cancer
Criteria 1 Solitary tumour
2 Tumour diameter of 2.0 cm
3 No bile duct or vascular invasiona
T1 All three criteria fulfilled
T2 Two of the three criteria fulfilled
T3 One of the three criteria fulfilled
T4 None of the criteria fulfilled
aInvasion of the bile duct, portal vein or hepatic vein is determined by
macroscopic examination of the resected specimen.
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nodules, major vascular invasion, MVI, tumour invasion into
adjacent organs, and rupture of HCC. When all of these 14 clin-
icopathological factors were entered into multivariable analysis,
tumour factors found to retain independent prognostic influence
were MVI, tumour multiplicity, bilobar tumours, tumour diam-
eter of >5.0 cm and symptomatic presentation (Table 7).
In each of the four staging systems (the fifth, sixth and seventh
editions of the AJCC and the LCSGJ TNM staging systems), DFS
diminished progressively with advancing T-stage. With the fifth
AJCC TNM system (Table 1), 1-, 3- and 5-year survival rates were
78.5%, 64.6% and 52.3%, respectively, in patients with T1
tumours, 81.8%, 59.9% and 50.3%, respectively, in patients with
T2 tumours, 46.0%, 24.2% and 18.1%, respectively, in patients
Table 5 Clinicopathological features of the 754 patients with hepa-
tocellular carcinoma (HCC) included in the present study
Age, years, median (range) 54 (19–82)
Gender (male : female) 608:146
HBsAg positivity, n (%) 649 (86.1%)
HCC detected on screening, n (%) 219 (29.0%)
Child–Pugh class, n (%)
A 729 (96.7%)
B 25 (3.3%)
Total bilirubin, mmol/l, median (range) 12 (2–61)
Albumin, g/l, median (range) 41 (17–53)
Aspartate transaminase, U/l, median (range) 48 (13–768)
Alpha-fetoprotein, ng/ml, median (range) 128 (1–1 335 900)
Platelet count ¥ 109/l, median (range) 174 (27–686)
Indocyanine green retention at 15 min,
%, median (range)
10.4 (1.2–78.0)
Tumour size, cm, median (range) 6 (0.5–28.0)
With tumour of 5.0 cm, n (%) 342 (45.4%)
With tumour of >5.0 cm, n (%) 412 (54.6%)
With solitary tumour, n (%) 564 (74.8%)
With  3 tumour nodules, n (%) 120 (15.9%)
With ruptured HCC, n (%) 52 (6.9%)
Major vascular invasion, n (%) 45 (6.0%)
Microvascular invasion, n (%) 337 (44.7%)
Invasion into adjacent organs, n (%) 45 (6.0%)





Not available 28 (3.7%)
Liver status, n (%)
Normal 90 (11.9%)
Chronic hepatitis 267 (35.4%)
Cirrhosis 397 (52.7%)
Table 6 Univariable analysis for disease-free survival (DFS) in hepa-
tocellular carcinoma (HCC)
Factors 5-year DFS P-value
Age 55 years (n = 407) 34.6% 0.094
Age >55 years (n = 347) 27.6%
Male (n = 608) 29.6% 0.052
Female (n = 146) 38.9%
Hepatitis B virus negative (n = 98) 28.5% 0.939
Hepatitis B virus positive (n = 649) 32.2%
Child–Pugh class A (n = 729) 31.8% 0.233
Child–Pugh class B (n = 25) 19.2%
Asymptomatic (n = 320) 43.4% <0.0001
Symptomatic (n = 434) 22.5%
Total bilirubin 12 mmol/l (n = 416) 32.7% 0.042
Total bilirubin >12 mmol/l (n = 338) 29.8%
Albumin 41 g/dl (n = 439) 27.7% 0.032
Albumin >41 g/dl (n = 315) 36.5%
Aspartate transaminase 48 U/l (n = 379) 40.6% <0.0001
Aspartate transaminase >48 U/l (n = 375) 22.1%
Alpha-fetoprotein 400 ng/ml (n = 455) 33.4% 0.001
Alpha-fetoprotein >400 ng/ml (n = 294) 27.9%
Platelet count 174 ¥ 109/l (n = 378) 31.7% 0.989
Platelet count >174 ¥ 109/l (n = 376) 31.1%
Indocyanine green retention at 15 min
10.5% (n = 372)
34.7% 0.062
Indocyanine green retention at 15 min
>10.5% (n = 360)
27.2%
With tumour 5.0 cm (n = 342) 42.9% <0.0001
With tumour >5.0 cm (n = 412) 21.8%
With tumour 2.0 cm (n = 83) 49.4% 0.011
With tumour >2.0 cm (n = 671) 29.2%
With solitary tumour (n = 564) 37.2% <0.0001
With multiple tumours (2) (n = 190) 14.2%
Unilobar HCC (n = 657) 33.6% <0.0001
Bilobar HCC (n = 97) 16.5%
No ruptured HCC (n = 702) 33.0% <0.0001
With ruptured HCC (n = 52) 9.6%
No major vascular invasion (n = 709) 32.7% <0.0001
With major vascular invasion (n = 45) 11.1%
No microvascular invasion (n = 417) 43.6% <0.0001
With microvascular invasion (n = 337) 15.6%
No invasion into adjacent organs (n = 709) 32.3% 0.006
With invasion into adjacent organs (n = 45) 17.8%
Resection margin 1.0 cm (n = 411) 30.4% 0.141
Resection margin >1.0 cm (n = 309) 33.3%
HCC well differentiated (n = 170) 37.1% 0.003
HCC not well differentiated (n = 539) 29.3%
Liver normal (n = 90) 27.8% 0.709
Liver not normal (n = 664) 31.9%
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with T3 tumours, and 31.1%, 15.6% and 11.9%, respectively, in
patients with T1 tumours (Fig. 1). There were significant differ-
ences in DFS between subgroups of patients with T2 and T3
tumours (P < 0.001), and between those with T3 and T4 tumours
(P = 0.001). However, the survival difference between patients
with T1 and T2 tumours was not significant (P = 0.315).
With the sixth AJCC TNM staging system (Table 2), 1-, 3- and
5-year survival rates were 81.6%, 60.3% and 50.6%, respectively, in
patients with T1 tumours, 50.7%, 27.9% and 21.0%, respectively,
in patients with T2 tumours, 28.7%, 18.0% and 13.9%, respec-
tively, in patients with T3 tumours, and 36.6%, 17.2% and 12.9%,
respectively, in patients with T4 tumours (Fig. 2). Patients with T1
tumours had a significantly better survival outcome than those
with T2 tumours (P < 0.001), and patients with T2 tumours had a
significantly better survival outcome than those with T3 tumours
(P = 0.001). However, the survival curves for patients with T3 and
T4 tumours almost overlap one another (P = 0.899), which sug-
gests that tumours at these two stages entailed similar prognoses.
As the sixth and seventh (Table 3) AJCC TNM staging systems
use the same T-stage classifications for T1 and T2 tumours, long-
term survival rates for patients with T1 and T2 tumours remained
unchanged between these two editions of the TNM staging
system. Major changes occurred with T3 tumours. Rates of 1-, 3-
and 5-year survival were 31.5%, 19.1% and 14.6%, respectively, in
patients with T3a tumours, 21.2%, 15.2% and 12.1%, respectively,
in patients with T3b tumours, and 36.6%, 17.2% and 12.9%,
respectively, in patients with T4 tumours (Fig. 3). There was a
significant survival difference between patients with T2 and T3a
tumours. However, the survival differences among patients with
T3a, T3b and T4 tumours were not statistically significant.
With the Japanese TNM staging system, 1-, 3- and 5-year DFS
rates were 75.6%, 62.8% and 50.0%, respectively, in patients with
T1 tumours, 67.1%, 43.5% and 36.3%, respectively, in patients
with T2 tumours, 33.5%, 18.4% and 12.8%, respectively, in
patients with T3 tumours, and 23.1%, 19.2% and 15.2%, respec-
tively, in patients with T4 tumours. Patients with T2 tumours had
significantly better survival than those with T3 tumours (P <
0.001). Survival rates in patients with T1 and T2 tumours differed
insignificantly (P = 0.330). The survival difference between
patients with T3 and T4 tumours was also not significant
(P = 0.300).
Table 7 Multivariable analysis for disease-free survival in hepatocel-
lular carcinoma (HCC)
Factors P-value HR 95% CI
Albumin 0.017 0.978 0.961–0.996
Platelet count <0.001 0.998 0.996–0.999
Tumour >5.0 cm 0.003 1.037 1.012–1.061
Bilobar HCC 0.035 1.304 1.019–1.670
Symptomatic HCC 0.004 1.355 1.099–1.670
Multiple tumours <0.001 1.633 1.349–1.976
Microvascular invasion <0.001 1.910 1.592–2.291
HR, hazard ratio; 95% CI, 95% confidence interval.
Figure 1 Disease-free survival in the study cohort (n = 754) accord-
ing to the fifth edition of the American Joint Committee on Cancer
tumour–node–metastasis (TNM) staging system
Figure 2 Disease-free survival in the study cohort (n = 754) accord-
ing to the sixth edition of the American Joint Committee on Cancer
tumour–node–metastasis (TNM) staging system
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Proposal of a new tumour staging system
In view of the inadequacy of all current staging systems in strati-
fying patients with surgically resectable HCC, a refined T-staging
system was proposed based on the multivariable analysis of the
present study (Table 8). The five tumour-related factors (MVI,
tumour number, lobar distribution, tumour size, symptomatic
presentation) that had the greatest impact on survival formed the
foundation of the refined system. Serum albumin level and plate-
let count were not included because the majority of patients
(>90%) in the present study had Child–Pugh class A cirrhosis only
and thus the prognostic influence of their liver function would be
limited. By contrast, as MVI was identified as the most powerful
prognostic factor for DFS, it was selected as the main stratifier for
T-staging. Five-year DFS rates in patients with and without MVI
were 44.0% and 15.6%, respectively (P > 0.001).
In the absence of MVI, the size of a solitary tumour had a
significant correlation with survival (Fig. 4). Five-year DFS
according to tumour size was 51.5%, 55.8%, 44.9% and 23.1%,
respectively, in patients with tumours of 2.0 cm, 2.1–5.0 cm,
5.1–10.0 cm and10.0 cm (P = 0.001). Based on these findings, a
solitary tumour without MVI was classified as T1. The next step
was to define the most appropriate tumour size to be used as the
cut-off limit for stratification. The sensitivity of different tumour
sizes from 1.0 cm to 6.0 cm was estimated by the receiver operat-
ing characteristic curve (Table 9). The sensitivity of tumour size at
5.0 cm was 66.0%, which was the highest. Hence, a size of 5.0 cm
was chosen as the cut-off value for T1 tumours. Five-year survival
Figure 3 Disease-free survival in the study cohort (n = 754) accord-
ing to the seventh edition of the American Joint Committee on
Cancer tumour–node–metastasis (TNM) staging system
Table 8 Proposed refined T-staging system for primary liver cancer
T1 Single tumour 5.0 cm without microvascular invasion
T2 Single tumour >5.0 cm without microvascular invasion
Or single tumour 5.0 cm with microvascular invasion
Or unilobar multiple tumours without microvascular invasion
T3 Single tumour >5.0 cm with microvascular invasion
T4 Unilobar multiple tumours with microvascular invasion
Or bilobar tumours
Or tumour invasion into a branch of the portal or hepatic vein
Or tumour invasion into an adjacent organ except the
gallbladder or rupture into the peritoneal cavity
Figure 4 Impact of tumour size on disease-free survival in patients
with solitary tumours without microvascular invasion
Table 9 Sensitivity of different tumour sizes used as cut-off values
for stratification
Cut-off valuea AUC, % P-value 95% CI
1.0 cm 61.5% 0.211 47.0–76.0%
2.0 cm 63.6% <0.001 58.0–69.2%
3.0 cm 64.1% <0.001 59.9–68.3%
3.5 cm 63.6% <0.001 59.5–67.7%
4.0 cm 64.3% <0.001 60.3–68.3%
4.5 cm 64.9% <0.001 61.0–68.8%
5.0 cm 66.0% <0.001 62.1–69.9%
5.5 cm 65.4% <0.001 61.5–69.3%
6.0 cm 65.8% <0.001 61.9–69.8%
aSize of largest tumour.
AUC, area under the curve; 95% CI, 95% confidence interval.
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rates in patients with tumours of 5.0 cm without MVI and
patients with tumours of >5.0 cm without MVI were 42.9% and
21.8%, respectively (P < 0.001).
Five-year survival rates in patients with a solitary tumour of
5.0 cm with MVI, patients with a solitary tumour of >5.0 cm
without MVI, and patients with unilobar multiple tumours
without MVI were comparable (30.4%, 38.3% and 28.3%, respec-
tively; P = 0.110). Because of the comparable survival rates, these
three groups of tumours were all classified as T2 tumour. As
the present analysis showed no significant correlation between
tumour size and survival in patients with multiple tumours with
(P = 0.651) or without (P = 0.384) MVI, it was considered unnec-
essary to set a cut-off limit for tumour size for multiple tumours.
The next steps involved the definitions of T3 and T4 tumours.
Patients with a solitary tumour of >5.0 cm with MVI had a worse
prognosis than those with unilobar multiple tumours without
MVI (5-year survival rates: 15.1% and 28.3%, respectively; P =
0.013), but a better prognosis than those with unilobar multiple
tumours withMVI (5-year survival rates: 15.1% and 8.4%, respec-
tively; P = 0.022) (Fig. 5). By contrast, patients with unilobar
multiple tumours with MVI had a similar survival outcome to
those with bilobar tumours (5-year survival rates: 8.4% and
16.5%, respectively; P = 0.055). Hence, a solitary tumour of
>5.0 cm with MVI was classified as T3 disease, and unilobar mul-
tiple tumours with MVI and bilobar tumours were classified as T4
disease. Also classified as T4 were tumours with pathological fea-
tures such as tumour rupture, invasion of adjacent organs, or
invasion into a branch of the portal or hepatic vein. Advanced
HCC as such is often manifested by symptoms (100% of patients
with major vascular invasion and 95.7% of patients with tumour
rupture or tumour invasion into adjacent organs were sympto-
matic), and symptomatic presentation was a significant prognos-
tic factor for DFS on multivariable analysis. Hence, tumours with
these pathological characteristics were grouped together as repre-
senting T4 disease.
Using the refined T-staging system, 1- and 5-year DFS rates
(Fig. 6) were 84.8% and 52.2%, respectively, in patients with
T1 tumours, 69.6% and 37.1%, respectively, in patients with
T2 tumours, 41.5% and 15.1%, respectively, in patients with T3
tumours, and 29.4% and 11.2%, respectively, in patients with T4
tumours (P < 0.001). The corresponding 1- and 5-year overall
survival rates were 99.5% and 82.3%, respectively, in patients with
T1 tumours, 93.8% and 62.9%, respectively, in patients with
T2 tumours, 82.1% and 38.7%, respectively, in patients with T3
tumours, and 68.2% and 26.5%, respectively, in patients with T4
tumours (P < 0.001).
With respect to ability to predict DFS, the refined T-staging
system ranked the highest of all five systems in the Cox regression
analysis (-2 log-likelihood: 6700.01; P = 0.013) (Table 10). Its
Kendall’s tau rank correlation coefficient also ranked the highest
[Kendall’s tau (t) coefficient: -0.355; P < 0.001] (Table 11). These
results indicate that the refined T-staging system achieved the
closest association with DFS in the study cohort of all the staging
systems considered.
Validation of the proposed T-staging system
In order to verify the refined T-staging system, a more recent
cohort of patients (n = 279) who underwent curative hepatic
resection between 1 June 2006 and 31 July 2009 were stratified
accordingly. All patients were subject to 36 months of postop-
erative follow-up. As a result, 1- and 5-year DFS rates were 81.5%
and 55.1%, respectively, in patients with T1 tumours (n = 22),
67.4% and 38.7%, respectively, in patients with T2 tumours (n =
102), 60.9% and 16.2%, respectively, in patients with T3 tumours
(n = 87), and 29.2% and 13.5%, respectively, in patients with T4
tumours (n = 68). Likewise, 1- and 5-year overall survival rates
Figure 5 Comparison of survival among patients with a solitary
tumour of >5.0 cm with microvascular invasion (A; n = 146), unilobar
multiple tumours without microvascular invasion (B; n = 53), and
unilobar multiple tumours with microvascular invasion (C; n = 82)
Figure 6 Disease-free survival in the study cohort (n = 754) under the
refined T-staging system
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were 98.8% and 82.5%, respectively, in patients with T1 tumours,
89.5% and 61.4%, respectively, in patients with T2 tumours,
95.7% and 49.2%, respectively, in patients with T3 tumours, and
74.2% and 28.0%, respectively, in patients with T4 tumours. There
were significant differences in terms of disease-free (P < 0.001)
and overall (P < 0.001) survival among the four groups of
patients.
Discussion
This study evaluated the prognostic power of four TNM staging
systems, the fifth, sixth and seventh editions of the AJCC and the
Japanese staging system, and found that none of themwere able to
adequately stratify the study cohort into various subgroups with
clear differences in survival. Indeed, the suboptimal performance
of the AJCC TNM staging systems had been reported previously.
In 1994, Izumi et al. reported the failure of the fifth edition of the
AJCC TNM system to establish prognoses in 104 patients under-
going hepatic resection.21 In 2010, Li et al. reported the inad-
equacy of the sixth edition of the TNM staging system in
stratifying 298 patients subjected to hepatic resection for locally
advanced tumours (i.e. T3 and T4).22 In the present analysis, the
fifth edition of the AJCC TNM staging system was found to be
capable of stratifying patients with advanced-stage tumours, but
failed to distinguish between T1 and T2 tumours. By contrast, the
sixth and seventh editions were able to stratify patients with T1
and T2 tumours, but failed to show any survival difference
between patients with T3 and T4 tumours. In fact, T3 tumours are
defined in the same way in the sixth and seventh editions of the
AJCC TNM staging system, except that the later edition subclas-
sifies them into T3a (multiple tumours, any of which can be
>5.0 cm in size) and T3b (tumour invasion into a major branch of
the portal or hepatic vein). Nonetheless, the present analysis
showed that survival curves for T3a, T3b and T4 tumours derived
from the seventh edition of the TNM staging system approxi-
mated one another closely, displaying very slight differences in
patient survival among the three groups. Thus, the subclassifica-
tion of T3 tumours is not justified.
Tumour invasion into a branch of the portal or hepatic vein was
found to entail worse prognosis than tumour invasion into adja-
cent organs or tumour rupture into the peritoneal cavity. In fact,
the pronounced prognostic effect of portal vein invasion had been
confirmed by various studies.15,22,23 In a retrospective analysis of
13 772 patients submitted to hepatic resection for HCC, portal
vein invasion was found to be the most dominant prognostic
factor among factors including tumour size, tumour number and
degree of tumour cell differentiation.15 A previous report by the
present group also highlighted the understating of the prognostic
influence of portal vein invasion by TNM staging systems.16 Portal
vein invasion is a precursor to intrahepatic metastasis and is a
major risk factor for early recurrence after hepatic resection.23,24 By
contrast, tumour invasion into adjacent organs or perforation
into the peritoneal cavity is likely to manifest as spontaneous
rupture. An earlier study by the present group showed that
patients with spontaneously ruptured HCC could achieve long-
term survival if the initial rupture episode was controlled success-
fully and followed by a staged hepatic resection.25 As patients with
major vascular invasion and patients with tumour rupture or
tumour invasion into adjacent organs demonstrate similar sur-
vival, the present authors do not support the classifying of
tumours with these pathological features into different tumour
stages, as in the seventh AJCC system. Nonetheless, for the
purpose of counselling patients on their prognosis, it would be
Table 10 Correlations of different staging systems with disease-free survival by the Cox regression model
Staging system Regression Remaining variation
d.f. -2 log-likelihood d.f. Change in variation P-value
Full model 13 6677.61a
Refined 3 6700.01 10 22.40 0.0132
AJCC, 5th edition 3 6706.79 10 29.18 0.0012
AJCC, 6th edition 3 6718.44 10 40.83 <0.0001
AJCC, 7th edition 4 6716.30 9 38.69 <0.0001
LCSGJ 3 6776.25 10 98.64 <0.0001
aThe lesser discrepancy means a stronger correlation with disease-free survival.
d.f., degrees of freedom; AJCC, American Joint Committee on Cancer; LCSGJ, Liver Cancer Study Group of Japan.
Table 11 Kendall's tau rank correlation coefficients for all staging
systems
Staging system Kendall's tau (t)
coefficienta
P-value Rank
Refined -0.355 <0.0001 1
AJCC, 5th edition -0.346 <0.0001 2
AJCC, 6th edition -0.341 <0.0001 3
AJCC, 7th edition -0.341 <0.0001 3
LCSGJ -0.254 <0.0001 4
aA coefficient value of -1 suggests a strong inverse correlation and a
value of 0 suggests no correlation.
AJCC, American Joint Committee on Cancer; LCSGJ, Liver Cancer
Study Group of Japan.
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appropriate to classify tumours with invasion into adjacent organs
or rupture into the peritoneal cavity as T3b, and tumours with
portal vein invasion as T4.
This study also evaluated the Japanese TNM staging system,
which appears to be simpler to use than the AJCC systems. In
the Japanese staging system, points are allocated to elements
classifying the T-stage. The elements are tumour size, tumour
multiplicity, and major vascular or bile duct invasion. With this
staging system, patients with T2 and T3 tumours demonstrated
a significant difference in survival, but differences between
patients with T1 and T2 tumours, and between patients with T3
and T4 tumours were not significant. Such results may be
explained by the relatively small numbers of patients in the T1
and T4 groups in the study. Nonetheless, a major drawback of
the Japanese staging system is that it attributes equal prognostic
influence to tumour size, tumour number, and vascular or bile
duct invasion. The multivariable analysis in the present study
illustrated that these factors differ in the degree of their respec-
tive prognostic impacts. Another major pitfall of the Japanese
TNM staging system is that it bases its tumour classification
purely on the macroscopic appearance of tumours and does not
describe microscopic features. Such a staging system permits the
easy communication of prognostic information with patients
before surgery, but delivers a less precise prognosis. The lack of
detailed pathological data also undermines the system’s appro-
priateness for use in the design of drug trials for adjuvant
therapies.
In view of the insufficiency of the four staging systems in
patient stratification and prognosis, the present authors propose a
refined T-staging system based on the findings of the current
study. An important aspect of the refined system is that it reintro-
duces a cut-off value for tumour size for solitary tumours. In the
fifth edition of the AJCC staging system, a tumour size of 2.0 cm
is set as the cut-off value for solitary tumours, as well as multiple
tumours. In the sixth and seventh editions, the cut-off value for
multiple tumours is shifted from 2.0 cm to 5.0 cm, and there is no
cut-off for solitary tumours because the size of such tumours was
not considered to have prognostic influence. However, the present
study found that the size of solitary tumours had significant prog-
nostic impact, whereas the impact of the size of multiple tumours
was insignificant, irrespective of MVI status. Hence, the refined
system does not include a cut-value for the size of multiple or
bilobar tumours.
Also reintroduced in the refined system is lobar distribution.
Again, lobar distribution is recognized in the fifth but discarded
in the sixth and seventh editions of the AJCC system because its
clinical application is complex. Moreover, lobar distribution has
been reported to be irrelevant in prognosis.12 Despite such
claims, bilobar involvement in fact implies either multicentric
tumour occurrence or intrahepatic metastasis, both of which
indicate aggressive tumour behaviour. Hence, the disregard of
lobar distribution in T-staging would certainly jeopardize a sys-
tem’s accuracy.
Although the present refined T-staging system was subse-
quently validated in a more recent cohort of patients, it is subject
to a major drawback attributable to the fact that it was derived
from a single-centre experience using survival data pooled from a
patient population that was predominantly affected by HBV-
related HCC. The prognosis in HBV-related HCC is somewhat
different from that of hepatitis C virus (HCV)-related HCC
because there are differences in the respective disease aetiolo-
gies.26,27 Whether such a system is also applicable in areas in which
HCV infection is endemic should be clarified in future studies.
A comparison of the present findings with those of two land-
mark studies on pathological tumour staging12,15 shows that the
relatively low proportion of patients (11.1%) with very early-stage
HCC (i.e. tumour size of 2.0 cm) in the present study may have
affected the prognostic impact of different tumour sizes. Such
discrepancies in the distribution of tumour sizes between the
present study and other studies might be attributable to the
differences in the tumour sizes adopted as cut-off values in
the respective staging systems.
One of the merits of the present study is its long follow-up
period. All of the patients included had been followed for 60
months at the time of data analysis, which allowed sufficient time
to monitor the behaviour of tumours in each T-stage. Another
merit of the study refers to its use of a mono-centre experience in
the surgical management of HCC patients. The sixth edition of
the AJCC TNM staging system was developed using survival data
pooled from four different centres. A big disadvantage of a mul-
ticentre study is that it is difficult to standardize data for the
operative techniques used in hepatic resection among different
surgeons at the various centres. Variations in operative approach
may make a significant difference to longterm survival.28 For
instance, excessive intraoperative bleeding calls for blood trans-
fusion, which in itself promotes tumour recurrence after hepatic
resection and impairs longterm survival.29,30 Use of a standard-
ized operative approach is important if survival outcomes are
not to be affected by surgical confounding factors and such an
approach can be achieved more readily by a single team of
surgeons.17
By contrast with the studies by Vauthey et al.12 and Minagawa
et al.,15 DFS was selected as the primary endpoint for survival
analysis in the present study. Survival after tumour recurrence is
influenced by factors such as remnant liver function, tumour
characteristics and subsequent treatment strategy. To date, a
widely accepted treatment algorithm for tumour recurrence after
hepatic resection has yet to be developed and not all treatments
(i.e. salvage transplantation, repeated resection, local ablation) are
available at every centre. Hence, using overall survival as the
primary endpoint may not enable a fair and equal comparison of
survival outcomes among different centres or regions. However,
the T-staging system proposed in the present study demonstrated
a clear stratification of patients in terms of not only DFS, but also
of overall survival, indicating that it may be a clinically practicable
staging system.
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Conclusions
The performance of the AJCC TNM staging systemwith respect to
the prognosis of patients submitted to hepatic resection for HCC
remains subject to limitations. A refined T-staging system for
resectable HCC is therefore proposed and appears to be able to
achieve satisfactory patient stratification. Nonetheless, further
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